Bedford, Mass., Jan. 13, 2015 -- Hologic, Inc. (NASDAQ: HOLX), announced today that a study published in the Journal of ClinicoEconomics and Outcomes Research demonstrates the clinical and economic favorability of using Hologic 3D mammography for breast cancer screening. (Bonafede MM, Kalra VB, Miller JD, Fajardo LL. Value Analysis of Digital Breast Tomosynthesis for Breast Cancer Screening in a Commercially-Insured U.S. Population.ClinicoEconomics and Outcomes Research. January 12, 2015.) This new paper fills a substantial gap in the literature necessary for understanding the economic consequences and cost effectiveness of mammography screening using tomosynthesis technology.
In order to evaluate the system-wide financial impact of a Hologic 3D mammogram as a breast cancer screening modality, researchers from Truven Health Analytics, Yale University School of Medicine, and the University of Iowa College of Medicine developed an economic model based on real-world health insurance claims data that compared overall spending on women who received a Hologic 3D mammogram in conjunction with a traditional 2D digital mammogram versus those who received only a 2D digital mammogram.
The data for the economic model were derived from an analysis of two Truven Health Analytics MarketScan® Research Databases, and supplemented by additional information from published literature.
Following are some of the researchers’ findings from the economic modeling study:
· Significant Cost Savings. Using an incremental insurance reimbursement of $50 for a 3D mammogram, the base case cost savings for the use of the new technology amounted to $2.4 million per year for a 1 million member health plan. Extrapolating the savings per screened patient ($28.53) to a conservative estimate that one half of the approximately 39 million mammograms performed annually in the U.S. are for screening, suggests that the adoption of breast tomosynthesis could account for over $550 million saved annually in U.S. breast care healthcare costs.
· Health Plan Savings Are Primarily Based on Two Clinical Benefits of Using Hologic’s 3D Mammograms in Screening. When the researchers broke down the annual cost savings for a 1 million member health plan into components, they estimated the plan would save $5.5 million in avoiding follow up services and $1.2 million from the earlier detection of breast cancer. Assuming the incremental annual cost of the new technology is $4.2 million, the net annual plan savings is $2.4 million to a 1 million member health plan.
· Substantial Human Impact. In addition to the cost savings from reduced unnecessary resource utilization following a screening mammogram, a reduction in follow-up services can also have a substantial human impact. For a 1 million member health plan, the authors estimate that 4,500 women could avoid unnecessary testing and/or treatment and the associated psychosocial experience of a false-positive mammogram.
“While the clinical advantages of Hologic’s 3D technology are significant and known, the economic advantages are becoming clearer as well,” said Peter J.Valenti III, Hologic Division President, Breast and Skeletal Health Solutions. "This study looks at the value of Hologic 3D mammography in breast cancer screening for women enrolled in commercial health insurance plans in the U.S. to assess its net budget impact. The analysis makes it clear that wider adoption of Hologic 3D mammography presents a significant opportunity to deliver value-based care in the U.S. health care system."
“Although not included in the analysis, the savings in the use of our new screening technology are even more significant if you factor in the direct costs paid by patients such as copayments, coinsurance, and deductibles and the indirect costs paid by patients for transportation to medical appointments, work absence, lost productivity, and childcare coverage,” Valenti noted. “In addition, there is growing evidence that the use of our 3D mammography system streamlines the diagnostic pathway expediting patient diagnostic workups and resulting in better patient throughput and resource utilization.”
About Hologic 3D Mammography:
While traditional 2D digital mammography is considered one of the most advanced breast cancer screening technologies available today, it provides only a two-dimensional picture of the breast. The breast is a three-dimensional object composed of different structures, such as blood vessels, milk ducts, fat, and ligaments. These structures, which are located at different heights within the breast, can overlap and cause confusion when viewed as a two-dimensional, flat image. This confusion of overlapping tissue is a leading reason why small breast cancers may be missed and normal tissue may appear abnormal, leading to unnecessary call backs.
A Hologic 3D mammography exam is the only breast tomosynthesis exam approved by the U.S. Food and Drug Administration as clinically superior to traditional 2D digital mammography. A Hologic 3D mammography exam has been shown in numerous clinical studies to significantly increase the detection of invasive breast cancers while simultaneously reducing recall rates across all patient populations and breast densities.
The technology was approved for breast cancer screening and diagnosis in the U.S. in February 2011 and has been available in countries recognizing the CE mark since 2008.
In October 2014, Hologic launched the “Genius” educational campaign to make it easier for women to ask for and find the most accurate mammography exam available. A Genius 3D mammography exam is available only on the Hologic Selenia Dimensions 3D system. Hologic 3D technology is in use in all 50 states and over 50 countries. Since 2011, over 8 million women in the U.S. have benefited from Hologic's Genius 3D mammography. For more information, visit www.genius3Dmammography.com.
About Hologic, Inc.:
Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The Company’s core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.
Hologic, 3D mammography, Dimensions, Genius 3D mammography, Selenia and associated logos are trademarks and/or registered trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
MarketScan is a registered trademark of Truven Health Analytics, Inc.
Disclosure. The authors report having no relevant affiliations or financial interest or financial conflict with the subject matter or materials discussed in the paper. Funding for the study was provided by Hologic, Inc.
Forward-looking Statement Disclaimer:
This News Release may contain forward-looking information that involves risks and uncertainties, including statements about the use benefits and financial impact of Hologic's 3D mammography (breast tomosynthesis) technology. There can be no assurance this product will achieve the benefits described herein and that such benefits will be replicated in any particular manner with respect to an individual patient as the actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.
Senior Director, Corporate Communications
Manager, Corporate Communications